Moreover, relapsing-remitting MS patients not taking a disease-modifying therapy, with an expanded disability status score (EDSS) of 3 or higher, had significantly higher numbers of CD4+IFN-γ+ T lymphocytes and CD8+IFN-γ+ T lymphocytes in peripheral blood in comparison to healthy controls and MS patients with an EDSS below 3 (92). This evidence concerns the gene CD8A and myeloid sarcoma.